Ocuphire Pharma EBITDA 2010-2024 | IRD

Ocuphire Pharma ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Ocuphire Pharma Annual EBITDA (Millions of US $)
2023	$-11
2022	$18
2021	$-23
2020	$-20
2019	$-4
2018	$-21
2017	$-17
2016	$-16
2015	$-18
2014	$-13
2013	$-9
2012	$-7
2011	$-16
2010	$-10
2009	$-7

Ocuphire Pharma Quarterly EBITDA (Millions of US $)
2024-06-30	$-8
2024-03-31	$-8
2023-12-31	$-5
2023-09-30	$6
2023-06-30	$-5
2023-03-31	$-6
2022-12-31	$-6
2022-09-30	$-5
2022-06-30	$-5
2022-03-31	$-7
2021-12-31	$-6
2021-09-30	$-4
2021-06-30	$-7
2021-03-31	$-5
2020-12-31	$-14
2020-09-30	$-2
2020-06-30	$-1
2020-03-31	$-3
2019-12-31	$5
2019-09-30	$-2
2019-06-30	$-3
2019-03-31	$-4
2018-12-31	$-5
2018-09-30	$-5
2018-06-30	$-5
2018-03-31	$-6
2017-12-31	$-5
2017-09-30	$-4
2017-06-30	$-4
2017-03-31	$-4
2016-12-31	$-4
2016-09-30	$-4
2016-06-30	$-4
2016-03-31	$-5
2015-12-31	$-4
2015-09-30	$-5
2015-06-30	$-5
2015-03-31	$-4
2014-12-31	$-4
2014-09-30	$-3
2014-06-30	$-4
2014-03-31	$-3
2013-12-31	$-3
2013-09-30	$-2
2013-06-30	$-2
2013-03-31	$-2
2012-12-31	$-1
2012-09-30	$-2
2012-06-30	$-2
2012-03-31	$-2
2011-12-31	$-2
2011-09-30	$-3
2011-06-30	$-6
2011-03-31	$-4
2010-12-31	$-3
2010-09-30	$-2
2010-06-30	$-3
2010-03-31	$-2
2009-12-31	$-2
2009-09-30	$-1
2009-06-30	$-2
2009-03-31	$-1

Sector	Industry	Market Cap	Revenue
		$0.000B	$0.000B
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.

Stock Name	Country	Market Cap	PE Ratio
Fanhua (AIFU)	China	$0.086B	2.07
Top KingWin (WAI)	China	$0.008B	0.00
S&W Seed (SANW)	United States	$0.006B	0.00
Invo BioScience (NAYA)	United States	$0.004B	0.00